Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Taysha Gene Therapies Inc TSHA

Healthcare Biotechnology
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:TSHA)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 11 days ago

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire February 26, 2025

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

GlobeNewswire February 19, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 7, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 3, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 6, 2024

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2024

Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13

GlobeNewswire November 6, 2024

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 1, 2024
View More News ››

Opinion & Analysis (NDAQ:TSHA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TSHA)

Taysha Gene Therapies, Inc. (TSHA): Advancing a Promising Ge

http://beyondspx.com/2024/08/01/taysha-gene-therapies-inc-tsha-advancing-a-promising-gene-therapy-pipeline-for-rare-neurological...
MikeTester - August 2, 2024

Taysha Gene Therapies Announces Pricing of Public Offering o

Just In: $TSHA Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsDALLAS, June 26, 2024...
whytestocks - June 26, 2024

Taysha Gene Therapies Announces Proposed Public Offering of

Just In: $TSHA Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsDALLAS, June 25, 2024...
whytestocks - June 25, 2024

Taysha Gene Therapies Announces Positive Clinical Data Acros

NEWS: $TSHA Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing...
whytestocks - June 18, 2024

TSHA Price Target Alert: $9.00. Issued by Raymond James

Just In: $TSHA TSHA Price Target Alert: $9.00. Issued by Raymond James2024-04-09 05:00:04 ET Christopher Raymond from Raymond James...
whytestocks - April 9, 2024

TSHA....Looks like there's more paper to layout

the Greater Fool....90 cent paper
Iseneschal - August 24, 2023
View more Bullboard ››

Eminent Gold Corp.

Eminent Gold Corp.

Eminent Gold Corp. is a gold exploration company focused on the exploration and discovery of gold deposits in Nevada. The ...
View More »